Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Rate of progression in exfoliative glaucoma

Poster Details

First Author: S. Kostianeva BULGARIA

Co Author(s):    M. Konareva-Kostianeva   M. Atanassov                 

Abstract Details

Purpose:

To assess the rates of visual field progression in exfoliative open angle glaucoma followed more than 5 years with standard automated perimetry (SAP).

Setting:

Department of Ophthalmology, Medical University Plovdiv, Bulgaria

Methods:

Sixty eyes of 39 treated patients with exfoliative glaucoma (14 male and 25 female, mean age at the beginning 67.2 ± 7.2 years) were enrolled in this study. The mean follow up period was 7.31 ± 2.00 years. In 18 patients with unilateral glaucoma the affected eye was selected and in 21 patients with bilateral glaucoma both eyes were analysed. Using Humphrey field analyzer (programme 30-2) the visual field progression rates were calculated as slopes of mean deviation (MD) over time. All statistical analyses were performed using SPSS v. 22.0.

Results:

The mean rate of progression (RоP) in the study group was - 0,51 ± 0.85 dB/year (decibels per year) ranging from +1.9 to - 3.08 dB. Mean MD at the start of the series was -13.54±10.19 dB. Negative slope of MD values was observed in 76.7% of the eyes. RoP was independent of the baseline MD (p=0.648). Slow progression (RoP ≤ - 0.3 dB/year) was found in 13 eyes (21.7%) and moderate to fast progression – in 29 eyes (48.3%). Only 3.3% of the eyes progressed at rates worse than – 2.5 dB/year. There was a positive tail of no progressing of all eyes.

Conclusions:

There was a wide range of progression rates in treated patients with exfoliative glaucoma. We observed fast progression with RoP < 1dB/year in 25% of the affected eyes.

Financial Disclosure:

NONE

Back to Poster listing